Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2

Study Identifier
P15-764
CT.gov Identifier
NCT02945228
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Hepatitis
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18 - 99 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * HCV genotype 2 participants treated with paritaprevir/ritonavir/ombitasvir plus ribavirin in daily practice.
    Exclusion Criteria:
    * Participants who have been previously treated with paritaprevir/ritonavir/ombitasvir and ribavirin.

    Protocol Summary

    The main objective of this study is to evaluate the safety and effectiveness of paritaprevir/ritonavir/ombitasvir with ribavirin used for participants infected with chronic hepatitis C virus (HCV) genotype 2 in daily practice in Japan.

    Study Locations

    Location
    Status
    Location
    Aichi Medical University Hosp /ID# 161892
    Nagakute, Aichi-ken, Japan, 4801195
    Status
    Not applicable
    Location
    Matsuyama Red Cross Hosp /ID# 162953
    Matsuyama, Ehime, Japan, 7900826
    Status
    Not applicable
    Location
    NHO Kyushu Medical Center /ID# 162956
    Fukuoka, Fukuoka, Japan, 810-8563
    Status
    Not applicable
    Location
    Kurume University Hospital /ID# 164158
    Kurume-shi, Fukuoka, Japan, 830-0011
    Status
    Not applicable
    Location
    Kusunoki Hospital /ID# 158119
    Fujioka, Gunma, Japan, 3750024
    Status
    Not applicable
    Location
    National Hospital Organization Takasaki General Medical Center /ID# 160877
    Takasaki-shi, Gunma, Japan, 370-0829
    Status
    Not applicable
    Showing {first} - {last} of {total} Results